![Daniëlle Lankveld](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profilo
Daniëlle Lankveld has worked at Intravacc BV since 2013, where she currently holds the position of Chief Operating Officer since 2017.
Posizioni attive di Daniëlle Lankveld
Società | Posizione | Inizio |
---|---|---|
Intravacc BV
![]() Intravacc BV BiotechnologyHealth Technology Institute for Translational Vaccinology is a Dutch independent company that partners with clients in vaccine development, from discovery to pilot production to clinical studies. The non-profit company is based in Bilthoven, Netherlands. Intravacc designs and creates the best candidate organisms for vaccine strain, looking for the highest immunity, potency, and production yield. The company substantially reduces the risks and costs involved with developing vaccines by bridging the gap between concept and late-stage clinical studies. Intravacc's upstream processing expertise covers both bacterial and cell cultivation as well as virus propagation in reactors ranging from 1l up to 200l. The company's scientists design, develop, and improve vaccine formulations that are suitable for the intended administration route and stable upon storage. | Direttore operativo | 01/01/2017 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
Intravacc BV
![]() Intravacc BV BiotechnologyHealth Technology Institute for Translational Vaccinology is a Dutch independent company that partners with clients in vaccine development, from discovery to pilot production to clinical studies. The non-profit company is based in Bilthoven, Netherlands. Intravacc designs and creates the best candidate organisms for vaccine strain, looking for the highest immunity, potency, and production yield. The company substantially reduces the risks and costs involved with developing vaccines by bridging the gap between concept and late-stage clinical studies. Intravacc's upstream processing expertise covers both bacterial and cell cultivation as well as virus propagation in reactors ranging from 1l up to 200l. The company's scientists design, develop, and improve vaccine formulations that are suitable for the intended administration route and stable upon storage. | Health Technology |
- Borsa valori
- Insiders
- Daniëlle Lankveld